Torrent Pharma Acquires JB Chemicals in ₹25,689 Cr Mega Deal

What’s Happening

will buy a 46.39% stake in JB Chemicals from PE firm KKR for ₹11,917 cr (~₹1,600/share), and up to 2.8% from employees. It will also launch an open offer at ₹1,639.18/share (≈₹6,843 cr) to acquire another 26%. Upon merger, every 100 JB shares will convert into 51 Torrent shares Deal Size & Positioning At ₹25,689 cr valuation, this becomes India’s 2nd-largest pharma M&A, after Sun-Ranbaxy. Torrent will leap to India's 5th-largest pharma firm, acquiring chronic-therapy brands and a fast-growing CDMO business Why It Matters Chronic segment scale-up: JB brings strong franchise in rheumatology, gastroenterology, and new fringe areas like ophthalmology CDMO & global footprint: JB’s lozenge-based contract development model and international reach broaden Torrent’s horizons Synergy potential: Combining their portfolios, sales forces, and manufacturing can yield cost and revenue efficiencies . Market & Analyst Take Torrent Pharma shares rose ~4% on the announcement JB Chemicals shares dropped ~6–7%, reflecting the 9–11% discount in deal pricing Analyst views: Motilal Oswal calls it value-accretive but warns of dilution if debt-funded; sees limited immediate upside Nomura, Jefferies, HSBC are optimistic: Jefferies targets ₹3,740 (≈10% upside), while HSBC expects growth from the CDMO addition Funding & Execution A consortium of foreign banks (HSBC, SCB, Barclays) has lined up ₹20,000 cr in debt financing for the deal, rated at ~8% interest Torrent expects the acquisition to be EPS-accretive by FY28, assuming smooth integration Final Word Torrent is doubling down on M&A prowess—adding JB Chemicals’ chronic brands and robust CDMO model aligns with its strategic roadmap and strengthens its domestic base. The deal offers scale advantages but comes at a premium and requires successful integration. For long-term investors, it may be a compelling bet on consolidation in the pharma sector—if execution stays on track.